BillionToOne, Inc., a Menlo Park, Calif.-based molecular diagnostics company, closed a $55m Series B funding round.
The round, announced in June 2021, was led by existing investor Hummingbird Ventures and incoming investor Four Rivers Group with participation from Neotribe Ventures, Norwest Venture Partners, Y Combinator, and Libertus Capital.
The company is using the funds to expand its the clinical lab, as well as its commercial team nationwide.
Co-founded by Oguzhan Atay, Ph.D. and David Tsao, Ph.D., and also led by Jennifer Hoskovec, MS, CGC, Director of Medical Affairs, BillionToOne is a precision diagnostics company whose its patent-pending QCT molecular counter platform can count DNA molecules at the single-count level. Its flagship product, UNITY, is a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis (CF), spinal muscular atrophy (SMA), and hemoglobinopathies through maternal blood.
FinSMEs
12/07/2021